You are here

  • Home
  • >
  • Cardiovascular Disease Management

Cardiovascular Disease Management

Managing patients with cardiovascular disease (CVD) goes beyond treating their symptoms; it involves the ongoing management of their condition in order to help reduce the risk of potentially fatal events.

Consider that atrial fibrillation (AF) is associated with 5-fold increase in the risk of strokes.1 Similarly, within 3 months of hospitalization for deep vein thrombosis (DVT) or pulmonary embolism (PE), two-thirds of recurrent events occurred in the first month postdischarge.2 Among study patients who stopped taking prescribed anticoagulants, 29.1% experienced a recurrent VTE at 5 years, while 12% of all recurrent VTEs resulted in a fatal event.3

The tools and resources available through the Janssen CarePath Healthy Engagements program can help inform your patients about cardiovascular conditions. Effective management can help reduce the risk of cardiovascular events such as DVT and PE. You will also find additional resources designed to support improved care coordination among healthcare professionals to engage and align efforts around improving quality of care, transitions of care, and ultimately, patient outcomes. 

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. The material on this site is intended only as informational or as an educational aid and is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

The information on this site is intended for the use of healthcare professionals in the United States only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country.

Do not sell my personal information

© Janssen Pharmaceuticals, Inc. 2018       Site Last Updated Date: January 2019

Patient Engagement

View resources designed to activate patients to be engaged in the care management of CVD.

Learn More
Care Coordination

Explore resources designed to support improved care coordination efforts among providers and enhance communication between providers and patients.

Learn More

Janssen tools and resources have not been proven to improve outcomes and may not completely address the specific intervention activities listed on each page. Janssen tools or resources discussed should be evaluated against other available sources of information before decisions are made about how to approach patient care within your organization. Full descriptions of appropriate use and associated limitations are set forth in the respective tools and resources.

This information has been developed by Janssen Pharmaceuticals, Inc., and made widely available to support patient and provider education.

References:

  1. Sabaté E, ed. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
  2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
  3. Miller S. MAP: bad Rx decisions cost poor US states most. lab.express-scripts.com/insights/drug-options/map-bad-rx-decisions-cost-poor-us-states. Accessed December 14, 2017.
  4. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175-194.
  5. Hernandez-Tejada MA, Campbell JA, Walker RJ, Smalls BL, Davis KS, Egede LE. Diabetes empowerment, medication adherence and self-care behaviors in adults with type 2 diabetes. Diabetes Technol Ther. 2012;14(7):630-634.
Browse

Click here to browse the full library of available resources.

Browse All Resources